Top

Published in:

01-02-2019 | Original Article

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications

Authors: Martina Mandarano, Guido Bellezza, Maria Laura Belladonna, Benoit J Van den Eynde, Rita Chiari, Jacopo Vannucci, Giada Mondanelli, Vienna Ludovini, Ivana Ferri, Fortunato Bianconi, Rachele Del Sordo, Lucio Cagini, Elisa Albini, Giulio Metro, Francesco Puma, Angelo Sidoni

Published in: Virchows Archiv | Issue 2/2019

Abstract

Several cancers, especially non-small cell lung cancer (NSCLC), are able to escape the immunosurveillance of tumor-infiltrating lymphocytes (TILs); among the molecules involved, the indoleamine 2,3-dioxygenase 1 (IDO-1) and the programmed cell death ligand-1 (PD-L1) play a crucial role. These aspects are of great interest in the current immunotherapeutic era, therefore the current study analyses the TILs, IDO-1, and PD-L1 interactions and their correlations with clinicopathological parameters and prognosis in NSCLC. One hundred ninety-three NSCLC surgical specimens, formalin-fixed, and paraffin-embedded were assessed for TILs density, TILs localization, IDO-1 (clone 4.16H1), and PD-L1 (clone E1L3N) immunohistochemical expressions. This data was correlated with clinicopathological parameters, disease free, and overall survivals. IDO-1 and PD-L1 high expressions were related to the solid pattern of adenocarcinomas (respectively p = 0.036 and p = 0.026); high PD-L1 expression was correlated with squamous histotype (p = 0.048). IDO-1 overexpression correlated with former smokers (p = 0.041), higher adenocarcinoma stages (p = 0.039), and with both higher TILs density and PD-L1 expression (respectively p = 0.025 and p = 0.0003). A better prognosis was associated with TILs intratumoral or mixed localizations (p = 0.029). TILs localization affects NSCLC prognosis; the higher expression of IDO-1 and PD-L1 in poorly differentiated and more aggressive lung adenocarcinomas, as well as the correlation between high PD-L1 expression and squamous cell histotype, confirm the more efficient immunoescaping of these NSCLC subgroups.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, van Schil PE, Garg K, Austin JHM, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 6(2):244–285. https://doi.org/10.1097/JTO.0b013e318206a221 CrossRefPubMedPubMedCentral

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, de Marinis F (2017) Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an expert panel meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res 6(3):373–386. https://doi.org/10.21037/tlcr.2017.05.09 CrossRefPubMedPubMedCentral

Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y (2018) Immunohistochemistry of pulmonary biomarkers : a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 142(3):408–419. https://doi.org/10.5858/arpa.2017-0106-SA CrossRefPubMed

Dunn GV, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360CrossRefPubMed

Anguille S, Smits EL, Bryant C, van Acker H, Goossens H, Lion E, Fromm PD, Hart DN, van Tendeloo V, Berneman ZN (2015) Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev 67(4):731–753. https://doi.org/10.1124/pr.114.009456 CrossRefPubMed

D'errico G, Machado HL, Sainz B Jr (2017) A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clin Transl Med 6(1):3. https://doi.org/10.1186/s40169-016-0130-5 CrossRefPubMedPubMedCentral

Brambilla E, le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS (2016) Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol 34(11):1223–1230. https://doi.org/10.1200/JCO.2015.63.0970 CrossRefPubMedPubMedCentral

Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, Daniele L, Oliaro A (2009) Clinical significance of tumor-infiltrating lymphocytes in lung neoplasm. Ann Thorac Surg 87(2):365–372. https://doi.org/10.1016/j.athoracsur.2008.10.067 CrossRefPubMed

Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ, Xie CM, Hu QG (2016) Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non–small cell lung cancer. Oncotarget 7(12):13765–13781. https://doi.org/10.18632/oncotarget.7282 CrossRefPubMedPubMedCentral

10.

Levina V, Su Y, Gorelik E (2012) Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol:173029. https://doi.org/10.1155/2012/173029

11.

Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167–182. https://doi.org/10.1016/j.ejca.2017.01.011 CrossRefPubMed

12.

Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL (2017) Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer. Clin Cancer Res 23(2):370–378. https://doi.org/10.1158/1078-0432.CCR-16-0150 CrossRefPubMed

13.

Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34(3):137–143. https://doi.org/10.1016/j.it.2012.10.001 CrossRefPubMed

14.

Munn DH (2012) Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 4:734–745CrossRef

15.

Smith C, Chang MY, Parker K et al (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8):722–735. https://doi.org/10.1158/2159-8290.CD-12-0014 CrossRefPubMedPubMedCentral

16.

Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, Herve C, Gutierrez-Roelens I, Marbaix E, Sempoux C, van den Eynde BJ (2015) Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3(2):161–172. https://doi.org/10.1158/2326-6066.CIR-14-0137 CrossRefPubMed

17.

Fallarino F, Grohmann U, Puccetti P (2012) Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 42(8):1932–1937. https://doi.org/10.1002/eji.201242572 CrossRefPubMed

18.

Albini E, Rosini V, Gargaro M, Mondanelli G, Belladonna ML, Pallotta MT, Volpi C, Fallarino F, Macchiarulo A, Antognelli C, Bianchi R, Vacca C, Puccetti P, Grohmann U, Orabona C (2017) Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3 dioxygenase 1. J Cell Mol Med 21(1):165–176. https://doi.org/10.1111/jcmm.12954 CrossRefPubMed

19.

Tsao MS, Le Teuff G, Shepherd FA et al (2017) PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Ann Oncol 28(4):882–889. https://doi.org/10.1093/annonc/mdx003 CrossRefPubMedPubMedCentral

20.

Yang CY, Lin MW, Chang YL, Wu CT, Yang PC (2016) Programmed cell death-ligand 1 expression is associated with favourable immune microenviroment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 57:91–103. https://doi.org/10.1016/j.ejca.2015.12.033 CrossRefPubMed

21.

Callea M, Pedica F, Doglioni C (2016) Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer immunotherapy and challenges for pathologist: state of the art. Pathologica 108(2):48–58PubMed

22.

Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, Mouroux J, Vénissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopses of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153. https://doi.org/10.1093/annonc/mdv489 CrossRefPubMed

23.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7 CrossRefPubMed

24.

Teng MW, Ngiow SF, Ribas A et al (2015) Classifying cancers based on T cell infiltration and PD-L1. Cancer Res 75(11):2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255 CrossRefPubMedPubMedCentral

25.

Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, van Maerken T, Salmon I, Cuvelier CA, Demetter P (2012) Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 106(1):141–147. https://doi.org/10.1038/bjc.2011.513 CrossRefPubMed

26.

Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S (2013) Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immunother 62(5):829–837. https://doi.org/10.1007/s00262-013-1393-y CrossRefPubMedPubMedCentral

27.

Jacquemier J, Bertucci F, Finetti P, Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, van den Eynde B, Birnbaum D, Olive D, Xerri L (2012) High expression of indolamine 2,3-dioxygenase in the tumor is associated with medullary features and favourable outcome in basal-like breast carcinoma. Int J Cancer 130(1):96–104. https://doi.org/10.1002/ijc.25979 CrossRefPubMed

28.

Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, Kim JH, Bang SM, Lee JS, Lee KW (2016) Prognostic implications of immunosoppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19(1):42–52. https://doi.org/10.1007/s10120-014-0440-5 CrossRefPubMed

29.

Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip PY, Yu B, O’Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA (2015) PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89(2):181–188. https://doi.org/10.1016/j.lungcan.2015.05.007 CrossRefPubMed

30.

Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J (2016) Prognostic significance of PD-L1 in patients with non–small cell lung cancer: a large cohort study of surgically resected cases. J Thorac Oncol 11(7):1003–1011. https://doi.org/10.1016/j.jtho.2016.04.007 CrossRefPubMed

31.

Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H (2016) PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol 9(1):64–69. https://doi.org/10.1016/10.1016/j.tranon.2016.01.003 CrossRefPubMedPubMedCentral

32.

Chen Y, Mu C, Huang J (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98(6):751–755. https://doi.org/10.1700/1217.13499 CrossRefPubMed

33.

Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH (2015) Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 88(1):24–33. https://doi.org/10.1016/j.lungcan.2015.01.016 CrossRefPubMed

34.

Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, Fang YC, Chen XF, Liu GT (2015) The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol 41(4):450–456. https://doi.org/10.1016/j.ejso.2015.01.020 CrossRefPubMed

35.

McLaughlin JF, Schalper K, Carvajal-Hausdforf DE et al (2014) Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). J Clin Oncol 32(15):8064. https://doi.org/10.1200/jco.2014.32.15_suppl.8064 CrossRef

36.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491–3494PubMed

37.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TILs Working Group 2014 (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol 26(2):259–271. https://doi.org/10.1093/annonc/mdu450 CrossRefPubMed

38.

Astigiano S, Morandi B, Costa R, Mastracci L, D'Agostino A, Ratto GB, Melioli G, Frumento G (2005) Eosinophil granulocytes account for indoleamine 2,3-dioxygenase–mediated immune escape in human non-small cell lung cancer. Neoplasia 7(4):390–396. https://doi.org/10.1593/neo.04658 CrossRefPubMedPubMedCentral

39.

Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II (2018) Immunohistochemical and image analysis-based study demonstrate that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors. J Thorac Oncol 13(6):779–791. https://doi.org/10.1016/j.jtho.2018.03.002 CrossRefPubMed

40.

Volaric A, Gentzler R, Hall R, Mehaffey JH, Stelow EB, Bullock TN, Martin LW, Mills AM (2018) Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1. Am J Surg Pathol 42(9):1216–1223. https://doi.org/10.1097/PAS.0000000000001099 CrossRefPubMed

41.

Brunnström H, Johansson A, Westbom-Fremer S, Backman M, Djureinovic D, Patthey A, Isaksson-Mettävainio M, Gulyas M, Micke P (2017) PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol 30(10):1411–1421. https://doi.org/10.1038/modpathol.2017.59 CrossRefPubMed

42.

Osoegawa A, Hiraishi H, Hashimoto T, Takumi Y, Abe M, Takeuchi H, Miyawaki M, Okamoto T, Sugio K (2018) The positive relationship between γH2AX and PD-L1 expression in lung squamous cell carcinoma. In Vivo 32(1):171–177. https://doi.org/10.21873/invivo.11221 CrossRefPubMedPubMedCentral

43.

Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT (2017) Programmed death Ligand-1 (PD-L1) expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. Arch Pathol Lab Med 141(11):1529–1532. https://doi.org/10.5858/arpa.2017-0028-OA CrossRefPubMed

44.

Xie Q, Wang L, Zhu B, Wang Y, Gu J, Chen Z (2008) The expression and significance of indoleamine -2,3-dioxygenase in non small cell lung cancer cell. Zhongguo Fei Ai Za Zhi 11(1):115–119. https://doi.org/10.3779/j.issn.1009-3419.2008.01.025 CrossRefPubMed

45.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954 CrossRefPubMedPubMedCentral

46.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139 CrossRefPubMed

47.

Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non small cell lung carcinoma. Br J Cancer 94(2):275–280. https://doi.org/10.1038/sj.bjc.6602934 CrossRefPubMedPubMedCentral

48.

Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, Lin X, Hu D, Huang Y, Jiang K, Miao Q, Li C (2017) Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget 8(48):83986–83994. https://doi.org/10.18632/oncotarget.20233 CrossRefPubMedPubMedCentral

49.

Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL (2016) A quantitative comparison of antibodies to programmed cell death 1 ligand 1. JAMA Oncol 3:256. https://doi.org/10.1001/jamaoncol.2016.3015 CrossRef

50.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II (2017) A prospective, multi-institutional assessment of four assays for PD-L1 expression in NSCLC by immunohistochemistry. JAMA Oncol 3(8):1051–1058. https://doi.org/10.1001/jamaoncol.2017.0013 CrossRefPubMedPubMedCentral

51.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL (2016) Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2(1):46–54. https://doi.org/10.1001/jamaoncol.2015.3638 CrossRefPubMedPubMedCentral

Title: Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications
Authors: Martina Mandarano
Guido Bellezza
Maria Laura Belladonna
Benoit J Van den Eynde
Rita Chiari
Jacopo Vannucci
Giada Mondanelli
Vienna Ludovini
Ivana Ferri
Fortunato Bianconi
Rachele Del Sordo
Lucio Cagini
Elisa Albini
Giulio Metro
Francesco Puma
Angelo Sidoni
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 2/2019
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-018-2483-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Digital quantification of KI-67 in breast cancer

In this issue

Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes

Botryoid Wilms tumor: a non-existent “entity” causing diagnostic and staging difficulties

Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study

Implementation of modern tools in autopsy practice—the way towards contemporary postmortal diagnostics